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Abstract
Introduction: Pronounced extracellular acidosis reduces both cardiac contractility and the b-adrenergic response.
In the past, this was shown in some studies using animal models. However, few data exist regarding how the
human end-stage failing myocardium, in which compensatory mechanisms are exhausted, reacts to acute mild
metabolic acidosis. The aim of this study was to investigate the effect of mild metabolic acidosis on contractility
and the b-adrenergic response of isolated trabeculae from human end-stage failing hearts.
Methods: Intact isometrically twitching trabeculae isolated from patients with end-stage heart failure were
exposed to mild metabolic acidosis (pH 7.20). Trabeculae were stimulated at increasing frequencies and finally
exposed to increasing concentrations of isoproterenol (0 to 1 × 10-6 M).
Results: A mild metabolic acidosis caused a depression in twitch-force amplitude of 26% (12.1 ± 1.9 to 9.0 ±
1.5 mN/mm2; n = 12; P < 0.01) as compared with pH 7.40. Force-frequency relation measurements yielded no
further significant differences of twitch force. At the maximal isoproterenol concentration, the force amplitude was
comparable in each of the two groups (pH 7.40 versus pH 7.20). However, the half-maximal effective concentration
(EC50) was significantly increased in the acidosis group, with an EC50 of 5.834 × 10
-8 M (confidence interval (CI),
3.48 × 10-8 to 9.779 × 10-8; n = 9), compared with the control group, which had an EC50 of 1.056 × 10
-8 M (CI,
2.626 × 10-9 to 4.243 × 10-8; n = 10; P < 0.05), indicating an impaired b-adrenergic force response.
Conclusions: Our data show that mild metabolic acidosis reduces cardiac contractility and significantly impairs the
b-adrenergic force response in human failing myocardium. Thus, our results could contribute to the still-
controversial discussion about the therapy regimen of acidosis in patients with critical heart failure.
Introduction
For more than 100 years, pronounced extracellular acido-
sis has been known to depress contractility in the healthy
myocardium [1-3]. The mechanisms underlying this nega-
tive inotropic effect, however, are complicated by the fact
that changing the pH can modify many of the cellular sys-
tems involved in the excitation-contraction (EC) coupling
pathway, including both the delivery of Ca2+ to the myofi-
laments and the Ca2+ sensitivity of the myofilaments
[4-10]. Several Ca2+ transport systems are depressed at a
low pH, including the SR Ca2+-ATPase (SERCA), the rya-
nodine receptor (RyR), and the Na+/Ca2+ exchanger
(NCX) [6]. Therefore, acidosis has been shown to decrease
the cellular Ca2+ transient amplitude [1]. Kohlhardt and
co-workers [11] showed a significantly decreased cardiac
output induced by acidosis (pH 7.00) by almost 25% in
nonfailing cat hearts. An additional number of studies ver-
ified the decrease in contractility in other species [12-18].
Studies have also demonstrated that the beta-adrenergic
response is reduced by acidosis, although the number of
studies regarding this subject is limited [19-23].
Most of the studies investigating the effects of acidosis
on cardiac contractility were performed with rather low
pH values (for example, pH ≥7.00), which might be out of
the range that commonly and frequently occurs in clinical
practice, such as in peri- and postcardiac surgery. More-
over, to our knowledge, little is known regarding the
contractile behavior in vitro of the human myocardium
under mild metabolic acidotic conditions. We recently
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showed that a mild and thus clinically relevant metabolic
acidosis (pH 7.20) had no significant influence on the car-
diac contractility and isoproterenol response in isolated
trabeculae of the nonfailing ovine myocardium [24].
However, heart-failure patients are prone to develop
metabolic acidosis (for example, because of prolonged
extracorporeal circulation during cardiac surgery). In
on-pump surgery, pH changes are often observed, for
example, as a result of volume shifts and the systemic
inflammatory response syndrome (SIRS) [25-27].
Patients with severe heart failure are first treated conser-
vatively and, at some stage, with transplantation or left
ventricular assist device [28]. These patients represent a
special group that must be treated with care and safety.
After a long-standing illness, the compensatory mechan-
isms of these patients are often fully exhausted, and
hence, these patients may react differently and/or earlier
to pathophysiologic conditions. Moreover, heart-failure
patients often require acute catecholaminergic therapy
both during and after cardiac surgery. However, the
beta-adrenergic response under mild metabolic acidosis
has, to our knowledge, never been investigated in iso-
lated human failing myocardium. Therefore, the first
aim of our study was to explore how the contractility of
the human failing myocardium reacts to mild metabolic
pH changes. Moreover, and most important, the second
aim was to investigate the clinical relevance of the beta-
adrenergic response under mild metabolic acidosis, pos-
sibly to contribute basic knowledge to the controversy
surrounding the therapy regimen of mild metabolic
acidosis in critical heart-failure patients.
Materials and methods
Human failing myocardium
Eight end-stage human failing hearts were obtained from
patients undergoing heart transplantation. Inclusion cri-
teria were diagnosed terminal heart failure, listing for
transplantation (Eurotransplant criteria) due to dilated or
ischemic cardiomyopathy. Other cardiomyopathies were
excluded. The ejection fraction should have been less than
or equal to 30%. Patients were included when they were
older than 18 years. Paired experiments that always con-
sisted of two trabeculae isolated from the same human
heart were performed by using 24 isolated ventricular tra-
beculae. All patients received pharmacologic treatment
consisting of angiotensin-converting enzyme inhibitors/
AT1-receptor antagonists, b-adrenoceptor antagonists,
diuretics, digitalis, and/or antiarrhythmic agents. Patients’
clinical characteristics and drug regimens are listed in
Table 1. During surgery, all patients received anesthetics
and antibiotic prophylaxis. The ethical committee of the
University Hospital of Goettingen approved these experi-
mental procedures with human tissue. Furthermore,
informed consent was given by all patients for using their
heart for research purposes.
Muscle strip preparation
After explantation, hearts were stored and transported
in an iced-cooled cardioprotective solution (mM) con-
sisting of Na+ 152, K+ 3.6, Cl− 135, HCO3− 25, Mg2+
0.6, H3PO
4− 1.3, SO4
2− 0.6, Ca2+ 2.5, glucose 11.2, and
2,3-butanedione monoxime (BDM) 10. The tissue was
oxygenated with 95% O2 and 5% CO2. Thin ventricular
trabeculae were prepared as described previously [29].
Afterward, the trabeculae were isolated from the right
ventricle because of the high endocardial fibrosis that is
present in the left ventricle of human end-stage failing
hearts. In a dissection chamber containing a BDM-solu-
tion, ventricular trabeculae were prepared from the
same area of the hearts by using stereoscopic micro-
scopy [30,31].
Isometric force recordings
For isometric force recordings, the trabeculae were
mounted in a superfusion organ chamber between a
force transducer (Scientific Instruments, Heidelberg, Ger-
many) and a hook connected to a micromanipulator for
length adjustment. As previously described, the trabecu-
lae were superfused with a HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffering solution, pH
7.40 (mM: NaCl 116, KCl 5, NaH2PO4 2, MgCl2 1.2,
Na2SO4 1.2, NaHCO3 20, glucose 10, CaCl2 initially at
0.25 and after with a stepwise increase of 2.0), at a tem-
perature of 37°C and oxygenated with 100% O2 [24].
Contractions were caused by electrical field stimulation
(baseline, 1 Hz; 5 to 7 mV; STIM1, Scientific Instru-
ments). At 5-minute intervals, 0.25 mM Ca2+ was added
until the final concentration of 2.0 mM was reached.
After 30 minutes of equilibration time with an initial pre-
diastolic tension of 0.1 mN/mm2, the trabeculae were
gradually stretched until reaching the maximum steady-
state twitch force to improve comparability. When
steady-state twitch force was achieved, the superfusion
was completely changed with a HEPES solution with a
pH of either 7.40 (control group) or 7.20 (mild acidosis
group) (37°C, CaCl2 2.0 mM, oxygenated with 100% O2).
After reaching a steady-state force again, force-frequency
relation (FFR) measurements were obtained by using sti-
mulation frequencies of 1, 2, and 3 Hz. To measure the
b-adrenergic response, the trabeculae were exposed to
increasing concentrations of (±)-isoproterenol (Sigma
Aldrich, Munich, Germany) up to 1 × 10-6 M at a stimu-
lation frequency of 1 Hz. A custom-made software on
the LabVIEW platform (National Instruments Corpora-
tion, Austin, TX, USA) was used to record and analyze
the force of the isometric contractions.
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Statistical analysis
Detected force values were normalized to the cross-
sectional area of each trabecula (width × thickness ×π/4)
and are presented as either systolic force or diastolic ten-
sion in mN/mm2. Data are presented as mean ± standard
error of the mean (SEM) or confidence intervals (CIs) for
EC50 values. The Student paired t test or a two-way
repeated-measures ANOVA was performed to test for sta-
tistically significant differences. A value of P < 0.05 was
considered to be statistically significant. Statistics and
curve fits were obtained with GraphPad Prism 5 software
(GraphPad Software, Inc., La Jolla, CA, USA).
Results
Baseline conditions
No statistical difference in the cross-sectional dimensions
(width × thickness × 4/π) between the two pH groups was
detectable (pH 7.40 group, 0.61 ± 0.09 mm2 (n = 7), versus
pH 7.20 group, 0.61 ± 0.11 mm2 (n = 12); P = 0.97).
Twitch-force amplitude was not statistically different
before the pH solution change at 1 Hz in both groups,
with 13.9 ± 3.1 mN/mm2 for the pH 7.40 control group
and 12.1 ± 1.9 mN/mm2 for the pH 7.20 group (n = 7 ver-
sus n = 12, P = 0.65). For further analyses, force was nor-
malized to baseline values at 1 Hz to better distinguish the
effects of acidosis on myocardial contractility.
Immediate effects of mild acidosis on basal contractility
To measure the immediate changes in contractile behavior
with exposure to a mild acidotic pH, we changed the solu-
tion to a HEPES solution with a pH of 7.20. Figures 1A
and 1B show the original twitch-recordings of representa-
tive single twitches before and after the pH changes. In
the control group, the solution was also changed to a fresh
solution with pH 7.40 to minimize unspecific effects (for
example, those due to temperature differences). Our
results show that the mild acidotic pH caused a statisti-
cally significant decrease in the twitch force amplitude
from 12.1 ± 1.9 to 9.0 ± 1.5 mN/mm2, which corresponds
to a negative inotropic effect of 26% (n = 12; P < 0.01)
(Figure 1C). However, no significant decline was observed
in the twitch force within the control group (13.9 ± 3.1 to
13.6 ± 2.9 mN/mm2; n = 7; P = 0.50) (Figure 1C). Relaxa-
tion time (Figure 1D) and relaxation velocity (data
not shown) did not statistically differ between pH 7.40 and
pH 7.20.
Force-frequency relation
The force-frequency relation (FFR) was measured at fre-
quencies between 1 and 3 Hz. Original registrations of
isometrically twitching trabeculae in the presence of a
physiologic pH of 7.40 compared with a mild acidotic
pH of 7.20 are presented in Figure 2A and 2B. Both
groups showed a negatively shaped FFR, whereas stimu-
lation frequencies increased, as is typical for the failing
human myocardium (Figure 2C) [32]. Force amplitudes
decreased by 15% ± 10% for pH 7.40 and by 25% ± 8%
for pH 7.20 at 2 Hz and by 57% ± 10% and by 64% ±
8% at 3 Hz, compared with 1 Hz (n = 7 versus n = 8;
P = 0.30). For diastolic tension, the curves showed a
marked increase between 1 and 3 Hz (Figure 2D), repre-
senting the diastolic dysfunction in the failing myocar-
dium. Moreover, the diastolic tension increased by
26% ± 11% for pH 7.40 and by 39% ± 6% for pH 7.20 at
2 Hz, and by 109% ± 35% for pH 7.40 and 105% ± 25%
for pH 7.20 at 3 Hz (n = 7 versus n = 8; P = 0.48).
During increasing frequencies, the trabeculae had faster
relaxation times. However, relaxation parameters (such
as time to 90% relaxation, Figure 2E) did not signifi-
cantly differ between the two pH groups (pH 7.40, n =
7, versus pH 7.20, n = 8; P = 0.40).
b-Adrenergic response
Maximal twitch force
To verify the effect of mild metabolic acidosis on the
b-adrenergic response in the isolated human failing myo-
cardium, the trabeculae were exposed to increasing con-
centrations of the b-adrenergic agonist isoproterenol. In
Figure 3A and 3B, representative original registrations
are depicted in the presence of increasing concentrations
Table 1 Heart-failure patients’ clinical characteristics and previous drug regimens
Sex Age (years) EF (%) PCW (mm Hg) CI (L/min/m2) ACE-I AT1 b-B DIU DIG AMIOD
ICM m 51 20-25 n.a. n.a. + - - + - -
DCM m 41 25 17 2.14 + - + + - -
DCM m 58 5-10 26 2.09 - + + + + -
ICM m 52 15 n.a. n.a. + - + - - -
ICM m 63 20 20 2.24 + - + + - +
DCM f 57 15 n.a. 2.21 - + + + - -
DCM m 32 20 5 2.64 + - + + + -
ICM f 59 23 11 2.21 + - - + - +
ACE-I, angiotensin-converting enzyme inhibitor; AMIOD, amiodarone; AT1, AT1-receptor antagonist; b-B, b-blocker; CI, cardiac index; DCM, dilated cardiomyopathy;
DIG, digitalis; DIU, diuretic; EF, ejection fraction; ICM, ischemic cardiomyopathy; PCW, pulmonary capillary wedge pressure.
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of isoproterenol up to 1 × 10-6 M. In both groups,
the force amplitude increased with the increasing con-
centrations of isoproterenol until it reached a plateau
(Figure 3C). Twitch-force amplitudes that were normal-
ized to baseline increased by 160% ± 50% for pH 7.40
and by 161% ± 21% for pH 7.20 at the maximal isoproter-
enol concentration of 1 × 10-6 M (n = 9 versus n = 10;
P = 0.99; Figure 3C). Thus, the maximal twitch force in
response to isoproterenol was not significantly different
between the two pH groups (Figure 3C). Accordingly,
the diastolic tension did not differ between the groups
(Figure 3D). In the control group, a decrease of 13% ± 7%
occurred at the maximal b-adrenergic stimulation, and,
in the mild metabolic pH group, a decrease of 16% ± 7%
was seen, which reflects a physiologic run-down due to
the myofilament relaxation after maximal stretching (pH
7.40; n = 9 versus pH 7.20; n = 10; P = 0.69; Figure 3D).
Analyses of the relaxation kinetics (time to 90%
relaxation) yielded a statistically slower relaxation in the
mild acidotic group than in the control group, with pH
7.40 (at baseline: 329 ± 29 ms (pH 7.20) versus 273 ± 18
ms (pH 7.40), at maximal isoproterenol concentration:
237 ± 12 ms (pH 7.20) versus 218 ± 22 ms (pH 7.40); n =
9 versus n = 11; P < 0.1; Figure 3E).
Determination of the EC50
The maximum of the b-adrenergic force response was not
statistically different between a normal and a mild acidotic
pH, as described earlier. However, from a clinical point of
view, it is important to obtain more information regarding
the b-adrenergic force response within the ascending part
of the dose-response curve. Therefore, we also determined
the half-maximal effective concentration (EC50). A signifi-
cant rightward shift of the pH 7.20 curve was found (pH
7.40, n = 8 versus pH 7.20, n = 8; P < 0.05). The EC50 was
significantly increased to 5.834 × 10-8 M (CI, 3.48 × 10-8
to 9.779 × 10-8 M) compared with the control group, with
Figure 1 Immediate changes in pH. (A) Representative single twitches before and after changing extracellular pH. No obvious reduction of
developed tension is visible. (B) Representative single twitches after an acute pH change show a decrease of absolute developed tension due to
mild metabolic acidosis. (C) Mean values of relative force amplitude before and after pH change show a significant decrease of force amplitude
after changing to the mild acidotic solution. (D) Time to 90% relaxation before and after pH solution change yielded no statistical difference.
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1.056 × 10-8 M (CI, 2.626 × 10-9 to 4.243 × 10-8 M, n = 10
versus n = 9, P < 0.05, Figure 3F). Thus, the b-adrenergic
response of the isometrically contracting human failing
myocardium is significantly depressed under mild acidosis.
Discussion
The aim of this study was to investigate the extent to
which mild metabolic acidosis with a pH of 7.20 influ-
ences cardiac contractility and the b-adrenergic response
in human end-stage failing myocardium.
Our results show that acute mild acidosis impairs con-
tractility and the b-adrenergic response in trabeculae iso-
lated from human end-stage failing hearts. Changing the
superfusion from a physiologic pH to mild acidosis (pH
7.20) directly caused a significant depression in the
twitch-force amplitude. However, a mild acidotic pH had
no additional effect on the contractile behavior during
increasing frequencies (1 to 3 Hz). Although the force
amplitude at maximal concentrations of isoproterenol
was not altered by mild acidosis, a pH of 7.20 caused a
rightward shift of the isoproterenol dose response curve,
leading to a significantly increased EC50.
Immediate pH changes
Over the last decades, the influence of metabolic acido-
sis on cardiac contractility was intensively investigated
in different animal models [1,2,4,5,9,11,12,33]. In the
presence of an acidotic pH, a serious species-indepen-
dent decrease in contractility was found [11]. Therefore,
acidosis influences EC coupling and the Ca2+-myofila-
ment response [4,5,7-10]. Studies have shown that
acidosis inhibits almost every step of the cellular EC
coupling: Kentish and Xiang [15,17,18,34] found a
reduced Ca2+ release from the SR via RyR and a direct
inhibition of the SERCA by acidosis that slows Ca2+
uptake into the SR and found that the direct inhibition
of NCX by a pathologically low pH increases the
amount of intracellular Ca2+. This disturbance in the
Ca2+-myofilament response acidosis leads to a decrease
in the apparent sensitivity of the regulatory sites of tro-
ponin C to Ca2+ [2,13].
In the human failing myocardium, cardiac contractility
is reduced, and compensatory mechanisms are exhausted.
Cardiomyocytes of patients with end-stage heart failure
show a reduced SERCA activity and a downregulation of
the SERCA protein, whereas NCX activity was shown to
be upregulated [32,35-37]. These systems compete with
each other, leading to a cellular Ca2+ loss that is further
aggravated by the leakiness of the RyR in heart failure
[29]. Therefore, the failing myocardium is much more
susceptible to negative inotropic effects because of a
blunted contractile reserve subsequent to decreased
Figure 2 Force-frequency relation. (A, B) Representative single twitches show a decrease of force amplitude and an increase of diastolic
tension in both groups. (C) Relative force amplitudes at frequencies between 1 Hz and 3 Hz show a negatively shaped force-frequency relation.
(D) Diastolic tension normalized to the values recorded at the lowest frequency revealed no differences between the two groups. (E) Mean
values of time to 90% of relaxation do not differ significantly between the two pH groups.
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Figure 3 b-Adrenergic response. (A, B) Representative single twitches show an increase of force amplitude with increasing isoproterenol
concentrations in both groups, but faster in the pH 7.4 group. (C) Relative force amplitudes normalized to baseline force showed a sigmoid
shape with increasing isoproterenol. (D) Diastolic tension normalized to baseline revealed no differences between the groups: the tension
decreased minimally with increasing isoproterenol. (E) Time to 90% of relaxation was statistically significantly slower in the mild acidotic group
than in the control group with pH 7.40. (F) Half-maximal effective concentration (EC50) was statistically significantly different between the pH
groups.
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sympathetic sensitivity or a negative force-frequency rela-
tion. In addition, the dependence of H+ elimination from
H+/K+-ATPase may be increased in heart failure because
of the impaired function of the Na+/H+ exchange subse-
quent to increased [Na+]i [38].
Recently, we showed that an acute mild metabolic pH
shift to 7.20 did not influence cardiac contractility in
the isolated trabeculae of nonfailing ovine hearts [24].
The results of the current study with end-stage human
failing myocardium show a significant decrease in force
amplitude under comparable conditions. Because com-
pensatory mechanisms are exhausted in heart failure
after long-lasting intracellular remodeling, it seems that
acidotic effects cannot be adequately buffered.
Force-frequency relation
In our experiments, a negative force-frequency relation
and an abnormal increase in diastolic tension with
increasing stimulation frequencies was observed. Failing
human myocardium is well known to show this negative
force-frequency relation [39,40]. Hasenfuss et al. [39]
showed that the altered FFR results from a disturbed
excitation-contraction coupling as a result of reduced
SERCA activity [39]. At higher stimulation frequencies,
this reduced activity leads to a decreased calcium cycling
[40]. Thus, it could be suggested that mild metabolic
acidosis might induce further negative inotropic effects
during increasing stimulation frequencies. Conversely, in
our experiments, acidosis was already present at 1-Hz
basal pacing frequency, causing a negative inotropic
effect. Thus it could also be suggested that there might
not be additional effects on top of this. Indeed, we only
observed basal negative inotropic effects at 1-Hz stimula-
tion frequency, which was not further aggravated by
increasing stimulation frequencies.
We found no data in the literature in which the direct
effect of acidosis on the FFR was investigated, especially
not in the human heart failing myocardium. Morii et al.
[41] showed in their work that in intact rat ventricular
myocardium at increasing frequencies (3 to 5 Hz), the
intracellular pH decreased (pH <7.10). This pH decrease
generates a reduced Ca2+ sensitivity and yields a negative
FFR [41]. Our data suggest that, in contrast, a mild meta-
bolic acidosis does not further enhance the negative inotro-
pic effect in FFR in human end-stage failing myocardium.
b-Adrenergic response
In patients with severe heart failure, a prolonged increase
in the activation of the sympathetic nervous system and
therefore increased b-adrenergic hormone blood levels
leads to a desensitization to adrenergic stimulation [42].
This desensitization reduces the contractile reserves for
physical exertion and is also implemented by a selective
downregulation of myocardial b1-adrenergic receptors in
heart failure [43-46].
In our study, we found a delayed response to increasing
isoproterenol concentrations under acidotic conditions,
whereas the b-adrenergic maximal reached force ampli-
tude did not differ between the two pH groups. Acidosis
changes the relative binding affinities of inotropes and
vasopressors to adrenergic receptors [42]. A study that
investigated the effect of metabolic acidosis regarding the
response to different catecholamines showed that cate-
cholamines (norepinephrine, epinephrine, isoproterenol,
and phenylephrine) react unequally to mild metabolic
acidosis in a large-animal model [47]. They found that in
the presence of acidosis, epinephrine was the most
affected and that isoproterenol, as a potent, nonselective,
synthetic b-adrenergic agonist, was the least affected by
mild changes in pH.
The present study is, to our knowledge, the only series
of experiments that has investigated the catecholamine
response in end-stage failing human myocardium in the
presence of a mild metabolic acidosis. We could show
this effect by using isoproterenol. However, to get infor-
mation about the behavior of other catecholamines, an
additional series should follow. .
Therefore, this specially modified and extremely fragile
myocardium requires greater b-adrenergic stimuli to
reach the same force amplitude when the pH is mildly
decreased compared with a normal pH.
Clinical influence and relevance
The prolonged use of positive inotropes in patients with
chronic heart failure is well known to increase mortality
[48,49]. Hence, the American College of Cardiology/
American Heart Association and the European Society
of Cardiology recommend in their guidelines for the
diagnosis and management of chronic heart failure in
the adult that intravenous inotropic agents should not
be used routinely for patients with refractory end-stage
heart failure but for palliation of symptoms in these
patients [50,51]. One should consider that patients with
terminal heart failure are a very special and sensitive
patient group with a reduced capacity to react to b-
adrenergic stimulation.
Particularly critical times for heart-failure patients
undergoing on-pump cardiac surgery are those during
and after weaning from the cardiopulmonary bypass,
because a low cardiac-output syndrome can occur.
Because of cardiac ischemia, myocardial dysfunction
induced by cardioplegia, reperfusion injury, the presence
of nonrepaired preexisting cardiac disease, and the acti-
vation of coagulation cascades and inflammation, a phar-
macologic support can be necessary [52]. It is not
unusual for these patients to develop a systemic
Schotola et al. Critical Care 2012, 16:R153
http://ccforum.com/content/16/4/R153
Page 7 of 10
inflammatory response syndrome (SIRS) that may lead to
sepsis [25-27]. In this context, pH changes are quite com-
mon. The sepsis guidelines of different societies do not
recommend buffering when pH is higher than or equal to
7.15 to counteract the decrease in cardiac contractility
because the application of a pH buffer like bicarbonate
can also have negative side effects [53-56]. The guidelines
are also restrained to recommend a therapy for a pH
lower than 7.15. However, our data show that in the end-
stage heart, failing myocardium mild metabolic acidosis
(pH 7.20) already depresses contractility and causes a
delayed b-adrenergic response that might be of clinical
relevance. This special patient group often has an earlier
and more pronounced reaction to pathophysiologic con-
ditions, and therefore, patients in this group should be
treated individually according their underlying diseases.
Limitations
This study has several limitations. All hearts were
explanted as a result of organ transplantation for end-
stage heart failure. Therefore, this patient group is very
special, and its incidence in the clinical routine is not
common. Normally, cardiac surgery patients have a
more moderate form of heart failure in which some
compensatory mechanisms still work. Furthermore, we
artificially induced acidosis in vitro from which we
derived direct information about the effects of selective
acidosis on myocardial contractility. Therefore, our
results should be translated into a clinical situation with
cautiousness because acidosis in vivo is a part of a com-
plex process of myocardial impairment during shock
conditions and is associated with proinflammatory cyto-
kines and NO generation.
The data are preliminary and should be confirmed in
an in vivo model followed by a large clinical study.
However, to our knowledge, this is the first investiga-
tion that shows that an acute mild metabolic acidosis
has already had a negative influence on cardiac contrac-
tility and the b-adrenergic response in the isolated myo-
cardium of end-stage heart failure patients.
Conclusions
In the end-stage heart failing myocardium, a preexisting
acute mild metabolic acidosis with a pH of 7.20 leads to
a decrease in contractility and a delayed b-adrenergic
response. Our results may contribute to the controver-
sial discussion about the therapy regimen of acidosis,
particularly in this special patient group.
Key messages
• The present study shows that clinically relevant low
metabolic acidosis impairs myocardial contractility in
isolated human failing myocardium.
• Low metabolic acidosis delays the b-adrenergic
response of human failing myocardium.
• From our point of view, it seems to be important to
recognize patients with severe heart failure as a special
patient group that reacts very sensitively to pH changes
because of already exhausted compensatory
mechanisms.
• Our study should trigger clinical trials to investigate
possible treatment strategies for patients with heart fail-
ure in the critical situation of metabolic acidosis.
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